🇺🇸 FDA
Patent

US 9463193

Individual 5-fluorouracile dose optimization in folfiri treatment

granted A61KA61K31/4745A61K31/513

Quick answer

US patent 9463193 (Individual 5-fluorouracile dose optimization in folfiri treatment) held by INSTITUT DE CANCEROLOGIE DE L'OUEST expires Mon Oct 06 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
INSTITUT DE CANCEROLOGIE DE L'OUEST
Grant date
Tue Oct 11 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 06 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K31/4745, A61K31/513, A61K31/519, A61K39/39558